Prospective Randomized Clinical Trial of Fetal Atrial Flutter & Supraventricular Tachycardia Therapy (FAST RCT)
NCT02624765 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 105
Last updated 2024-05-22
Summary
The Fetal Atrial Flutter and Supraventricular Tachycardia (FAST) Therapy Trial is a prospective multi-center trial that examines the efficacy and safety of standard prenatal antiarrhythmic treatment. Study components of FAST include three prospective sub-studies to determine the efficacy and safety of commonly used transplacental drug regimens in suppressing fetal AF without hydrops (Randomized Clinical Trial (RCT) A), SVT without hydrops (RCT B), and SVT with hydrops (RCT C). All RCTs are open label phase III trials of standard 1st line therapy, which either is started as monotherapy (no hydrops) or as dual therapy (hydrops).
Conditions
- Fetal Atrial Flutter Without Hydrops
- Fetal Supraventricular Tachycardia Without Hydrops
- Fetal Supraventricular Tachycardia With Hydrops
Interventions
- DRUG
-
Digoxin (monotherapy)
Oral or IV loading dose: 0.5 mg q 12 h (total 4 doses over 48 hours) followed by Oral maintenance dose: 0.25 mg-1mg/day
- DRUG
-
Sotalol (monotherapy)
Oral dose: 80 mg TID or 120 mg BID (240 mg/day)
- DRUG
-
Flecainide (monotherapy)
Oral dose: 100 mg TID (300 mg/day)
- DRUG
-
Digoxin (dual therapy)
Oral or IV loading dose: 0.5 mg q 8 h (total 4 doses over 32 hours) followed by oral maintenance dose: 0.25 mg-1mg/day
- DRUG
-
Sotalol (dual therapy)
Oral dose: 160 mg BID (320 mg/day)
- DRUG
-
Flecainide (dual therapy)
Oral dose:100 mg TID (300 mg/day)
Sponsors & Collaborators
-
Canadian Institutes of Health Research (CIHR)
collaborator OTHER_GOV -
Edgar Jaeggi
lead OTHER
Principal Investigators
-
Edgar Jaeggi, MD · The Hospital for Sick Children, Toronto
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 16 Years
- Max Age
- 50 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2016-02-29
- Primary Completion
- 2024-03-31
- Completion
- 2024-03-31
- FDA Drug
- Yes
Countries
- United States
- Australia
- Canada
- Germany
- Netherlands
- United Kingdom
Study Locations
More Related Trials
-
INhalation of Flecainide to Convert Recent Onset SympTomatic Atrial Fibrillation to siNus rhyThm (INSTANT)
NCT03539302 ·Status: COMPLETED ·Phase: PHASE2
-
Pharmacokinetics, Pharmacodynamics, and Impact of Inorganic Nitrate on Exercise in HFpEF
NCT02256345 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of Sotalol in Children With Arrhythmia
NCT03895411 ·Status: UNKNOWN ·Phase: PHASE4
-
Feasibility and Safety of IV Sotalol Administered as a Loading Dose to Initiate Oral Sotalol Therapy
NCT04473807 ·Status: UNKNOWN ·Phase: PHASE4
-
Efficacy and Safety Study of Efgartigimod in Adults With Post-COVID-19 POTS
NCT05633407 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy of Vanoxerine for the Conversion of Subjects With Recent Onset Atrial Fibrillation or Flutter to Normal Sinus Rhythm
NCT02454283 ·Status: TERMINATED ·Phase: PHASE3
-
Rapid Atrial Fibrillation Treatment Strategy
NCT04092621 ·Status: UNKNOWN ·Phase: PHASE4
-
Safety and Efficacy Study of Once and Twice Daily Doses of MCC-135 in Subjects With Congestive Heart Failure.
NCT00050076 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy of Propafenone Versus Dronedarone for the Maintenance of Sinus Rhythm in Patients With Atrial Fibrillation
NCT01991119 ·Status: COMPLETED ·Phase: NA
-
Role of SNP and DIGOXIN Response in Atrial Fibrillation Patients
NCT02167165 ·Status: COMPLETED
-
Sub-Q Versus IV Furosemide in Acute Heart Failure
NCT02579057 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Comparing the Effects of Amiodarone, Sotalol, and Placebo in Maintaining Sinus Rhythm in Patients With Atrial Fibrillation Converted to Sinus Rhythm
NCT00007605 ·Status: COMPLETED ·Phase: PHASE3
-
Bolus vs IVP (Intravenous Push) Diltiazem for Atrial Fibrillation or Flutter
NCT04141553 ·Status: UNKNOWN ·Phase: PHASE4
-
Controlling Rapid Atrial Fibrillation With Dexmedetomidine
NCT04042727 ·Status: TERMINATED ·Phase: PHASE2/PHASE3
-
Comparison of Squat-to-Stand Maneuver With Amyl Nitrite, Valsalva, and Exercise Stress Echocardiography in Inducing Latent Left Ventricular Outflow Obstruction in Hypertrophic Cardiomyopathy
NCT04905173 ·Status: WITHDRAWN ·Phase: NA
-
Use of a Novel SUBCUTaneous Preparation of Furosemide to Facilitate Early Supported Discharge of Patients With Heart Failure
NCT05419115 ·Status: COMPLETED ·Phase: PHASE2
-
Clinical Efficacy of Potassium Canrenoate in Sinus Rhythm Restoration Among Patients With Atrial Fibrillation.
NCT03536806 ·Status: UNKNOWN ·Phase: PHASE4
-
PERceptions of Diltiazem Versus ADEnosine for Treatment of Supraventricular Tachycardia in the Emergency Department
NCT07086560 ·Status: RECRUITING
-
Flecainide Acetate Inhalation Solution for Cardioversion of Recent-Onset, Symptomatic Atrial Fibrillation
NCT05039359 ·Status: TERMINATED ·Phase: PHASE3
-
Safety Study of Intranasal Etripamil for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia (PSVT). NODE-302
NCT03635996 ·Status: TERMINATED ·Phase: PHASE3
-
Impact of Sodium-glucose Cotransporter 2 Inhibitors on Post-operative Atrial Fibrillation in Cardiothoracic Surgery
NCT06251453 ·Status: UNKNOWN
-
Comparing the Safety and Efficacy of ASI-02 to Agitated Saline for Suspected Right-to-left Shunt
NCT06938347 ·Status: RECRUITING ·Phase: PHASE3
-
Digoxin for Congenital Erythrocytosis Due to Up-Regulated Hypoxia Sensing
NCT03433833 ·Status: WITHDRAWN ·Phase: PHASE1
-
A Phase 1 Study Evaluating Eliglustat's Effects on Pharmacokinetics, Safety & Tolerability of Digoxin in Healthy Adults
NCT01357811 ·Status: COMPLETED ·Phase: PHASE1
-
Nitroglycerin vs. Furosemide Using Lung Ultrasound Pilot Trial
NCT03259165 ·Status: TERMINATED ·Phase: PHASE2